Encouraging early test for Nastech’s osteoporosis nasal spray
The study achieved its goal of demonstrating the ability to deliver the drug, PTH1-34, and produce a similar pharmacokinetic profile to Forteo, an already approved subcutaneous treatment for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.